

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

GUIDANCE EXECUTIVE (GE)

Consideration of consultation responses on review proposal

Review of TA235; Mifamurtide for the treatment of osteosarcoma

This guidance was issued October 2011 with a review date of November 2013.

Background

At the GE meeting of 22 October 2013 it was agreed we would consult on the review plans for this guidance. A four week consultation has been conducted with consultees and commentators and the responses are presented below.

Proposal put to consultees:	TA235 should be transferred to the 'static guidance list.
Rationale for selecting this proposal	No evidence has been identified that would lead to a change in the recommendations of the original guidance. No relevant ongoing studies have been identified.

GE is asked to consider the original proposal in the light of the comments received from consultees and commentators, together with any responses from the appraisal team. It is asked to agree on the final course of action for the review.

Recommendation post consultation:	TA235 should be transferred to the 'static guidance list.
--	---

Respondent	Response to proposal	Details	Comment from Technology Appraisals
Royal College of Nursing	No comment	Nurses caring for people with osteosarcoma were invited to comment on the proposals to move the above Appraisal Guidance to the static list. There are no comments to make on this proposal on behalf of the Royal College of Nursing.	No action required.
National Cancer Research Institute Royal College of Physicians Royal College of Radiologists Association of Cancer Physicians	Agree	The NCRI/RCP/RCR/ACP/JCCO agree that there is no new data on mifamurtide and that it is appropriate for it to be moved to the static list at present.	Comment noted.

No response received from:

<u>Manufacturers/sponsors</u> <ul style="list-style-type: none"> Takeda UK (mifamurtide) <u>Patient/carer groups</u> <ul style="list-style-type: none"> Action for Children Action for Sick Children 	<u>General</u> <ul style="list-style-type: none"> Allied Health Professionals Federation Board of Community Health Councils in Wales British National Formulary Care Quality Commission
--	---

<ul style="list-style-type: none"> • Action on Pain • Adam Dealey Foundation for Ewing Sarcoma • Afiya Trust • Anthony Pilcher Bone Cancer Trust • Black Health Agency • Cancer Black Care • Cancer Equality • Cancer52 • Children with Cancer • Children's Cancer & Leukaemia Group • Children's Society • CLIC Sargeant • Equalities National Council • Helen Rollason Cancer Charity • Independent Cancer Patients Voice • Limb Loss Information Centre (LLIC) • Macmillan Cancer Support • Maggie's Centres • Marie Curie Cancer Care • Muslim Council of Britain • Muslim Health Network • National Children's Bureau • Paget's Association (formerly National Association for the Relief of Paget's Disease) • Pain Concern • Pain Relief Foundation • Pain UK • Rarer Cancers Foundation • Sarcoma UK • South Asian Health Foundation 	<ul style="list-style-type: none"> • Commissioning Support Appraisals Service • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Medicines and Healthcare Products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • NHS Alliance • NHS Commercial Medicines Unit • NHS Confederation • Scottish Medicines Consortium <p><u>Comparator manufacturers</u></p> <ul style="list-style-type: none"> • Baxter Healthcare (ifosfamide) • Bristol-Myers Squibb (cisplatin) • Cephalon UK (doxorubicin) • Amdipharm Mercury (methotrexate) • Hospira UK (cisplatin, doxorubicin, methotrexate) • Medac (doxorubicin) • Pfizer (cisplatin, doxorubicin, methotrexate) • Teva UK (cisplatin, methotrexate) • Wockhardt UK (cisplatin, doxorubicin, methotrexate) <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • Bone Cancer Research Trust • Bone Research Society • Christopher Hardman Osteosarcoma Research Fund • Health Research Authority • Institute of Cancer Research • MRC Clinical Trials Unit
---	--

- Specialised Healthcare Alliance
- Teenage Cancer Trust
- Tenovus
- Together for Shorter Lives (previously ACT & Children's Hospices UK)
- WellChild

Professional groups

- Association of Anaesthetists
- Association of Surgeons of Great Britain and Ireland
- British Geriatrics Society
- British Institute of Musculoskeletal Medicine
- British Orthopaedic Association
- British Orthopaedic Oncology Society
- British Psychosocial Oncology Society (BPOS)
- British Sarcoma Group
- Cancer Network Pharmacists Forum
- Cancer Research UK
- Royal College of Anaesthetists
- Royal College of General Practitioners
- Royal College of Pathologists
- Royal College of Surgeons
- Royal Pharmaceutical Society
- Royal Society of Medicine
- UK Health Forum
- United Kingdom Clinical Pharmacy Association
- United Kingdom Oncology Nursing Society

Others

- Department of Health

- National Cancer Research Network
- National Institute for Health Research
- Research Institute for the Care of Older People

Assessment Group

- Assessment Group tbc
- National Institute for Health Research Health Technology Assessment Programme

Associated Guideline Groups

- National Collaborating Centre for Cancer

Associated Public Health Groups

- Public Health England
- Public Health Wales NHS Trust

<ul style="list-style-type: none">• NHS Camden CCG• NHS England• NHS Salford CCG• Welsh Government	
---	--

GE paper sign-off: Janet Robertson, Associate Director – Technology Appraisals Programme

Contributors to this paper:

Technical Lead: Christian Griffiths

Project Manager: Andrew Kenyon

16 December 2013